Update on the management of prostate cancer with goserelin acetate: patient perspectives

Figures & data

Table 1 Summary of androgen deprivation indications and recent changes

Less evidence for ADT in 2009	Still good uses for ADT in 2009
Localized dz – prior to prostatectomy^Citation21	Local/advanced dz – PSA > 50, PSADT < 12 mo^Citation29
Localized dz – prior to EBXRT, brachy tx^Citation24^–^Citation27	Local/advanced dz – prior to EBXRT^Citation43^–^Citation47
Localized dz – no primary treatment^Citation28	Local obstructive sx/metastatic disease^Citation52
Biochemical recurrence after tx, slow PSADT^Citation34	Biochem recurrence p tx, high-risk Cap death^Citation36^–^Citation38
	Lymph node involvement at prostatectomy^Citation49

Abbreviations: ADT, androgen deprivation therapy; EBXRT, external beam radiation; PSADT, prostate-specific antigen doubling time; dz, disease; tx, treatment; sx, symptoms; p, after; Cap, prostate cancer.

HeidenreichAGunnarABollaMEAU guidelines on prostate cancerEur Urol2008531688017920184

 PubMed Web of Science ®Google Scholar

StuderUEColletteLWhelanPUsing PSA to guide timing of androgen deprivation in patients with T0-4 N0-2 M0 prostate cancer not suitable for local curative treatment (EORTC 30891)Eur Urol200852594194918191322

 PubMed Web of Science ®Google Scholar

PilepichMVWinterKLawtonCAAndrogen suppression adjuvant to definitive radiotherapy in carcinoma – long-term results of phase III RTOG 85–31Int J Radiat Oncol Biol Phys20025351097110512128107

 PubMed Web of Science ®Google Scholar

BeasleyMWilliamsSGPicklesTExpanded risk groups help determine which prostate radiotherapy sub-group may benefit from adjuvant androgen deprivation therapyRadiat Oncol20083818423030

 PubMed Web of Science ®Google Scholar

D’AmicoAVLoffredoMRenshawAASix-month androgen suppression plus radiation therapy compared with radiation therapy alone for men with prostate cancer and a rapidly increasing pretreatment prostate-specific antigen levelJ Clin Oncol200624254190419516943536

 PubMed Web of Science ®Google Scholar

BollaMColletteLBlankLLong-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trialLancet20029327 360:10310612126818

 PubMed Web of Science ®Google Scholar

Lu-YaoGLAlbertsenPCMooreDFSurvival following primary androgen deprivation therapy among men with localized prostate cancerJAMA2008300217318118612114

 PubMed Web of Science ®Google Scholar

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators GroupBr J Urol19977922352469052476

 PubMedGoogle Scholar

SimmonsMNStephensonAJKleinEANatural history of biochemical recurrence after radical prostatectomy: risk assessment for secondary therapyEur Urol200751511758417240528

 PubMed Web of Science ®Google Scholar

SotoDEAndrigeRRPanCCIn patients experiencing biochemical failure after radiotherapy, pretreatment risk group and PSA velocity predict differences in overall survival and biochemical failure-free intervalInt J Radiat Oncol Biol Phys20087151295130118472361

 PubMed Web of Science ®Google Scholar

WilliamsSGBuyyounouskiMPicklesTKPercentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: statistical significance without predictive performanceInt J Rad Oncol Bio Phys200870411691175

 Web of Science ®Google Scholar

MessingEManolaJYaoJImmediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomyLancet Oncol20067647247916750497

 PubMed Web of Science ®Google Scholar